...in its history before raising $258.3 million in its IPO at a $1.1 billion postmoney valuation.Vor Biopharma Inc....
...for cancer.As a group, the 10 companies raised nearly $1.9 billion. Paul Bonanos Immunocore Holdings Ltd. Sana Biotechnology Inc. Vor Biopharma Inc. Pharvaris...

...biotechs due to trade on Friday: Immunocore Ltd., Sensei Biotherapeutics Inc., Terns Pharmaceuticals Inc. and Vor Biopharma...

...Friday, ready to test investors’ appetite anew following a record-setting year for IPOs. At $150 million, Vor Biopharma Inc....
...listing on NASDAQ. Winnie Pong Lucira Health Inc. LumiraDx Ltd. Angion Biomedica Corp. Immunocore Holdings Ltd. Pharvaris N.V. Terns Pharmaceuticals Inc. Bolt Biotherapeutics Inc. Vor Biopharma Inc. Decipher...

...Inc.’s SAB and serves as a Columbia University hematologist and oncologist. He is also a co-founder of Vor Biopharma...

...of Passage Bio Inc. (NASDAQ:PASG), succeeds Pierluigi Paracchi, who will remain Genenta’s CEO. Stem cell company Vor Biopharma Inc....

...the company announced a non-exclusive preclinical partnership with Vor Biopharma Inc....
...and Jillian Banfield University collaborators: N/ACorporate partners: Vor Biopharma...

...at Columbia University, a prolific author of non-fiction articles and books and scientific co-founder of Vor Biopharma Inc....
...within Indian hospitals to manufacturer cell therapies and to train staff to administer them. Steve Usdin 5AM Ventures Vor Biopharma Inc. Immuneel...

...Quiroz as EVP and CMO, a new position. He was CMO of Solid Biosciences Inc. (NASDAQ:SLDB).Vor Biopharma Inc....
...the hematological malignancies company in 2017 as director of operations. Robin Sawka Kymera Therapeutics Inc. Immunovia AB Apic Bio Inc. Vor Biopharma Inc. Organogenesis...

...a $150 million series B round in June (see “Crossovers Pile into New Rounds” ). Vor Biopharma Inc....
...binding Ig like lectin 15 Robin Sawka, BioCentury Staff Waters Corp. Vertex Pharmaceuticals Inc. C4 Therapeutics Inc. Scholar Rock Holding Corp. Vor Biopharma Inc. Autobahn...

...PureTech Health plc (LSE:PRTC). CEO Robert Ang and 5AM's Kush Parmar declined to discuss whether Vor Biopharma Inc.'s...
...develop its own targeted cancer therapies internally, said Ang. Targets CD33 (SIGLEC3) Sandi Wong, Assistant Editor 5AM Ventures Vor Biopharma Inc. PureTech...